ASX:BXN

Bioxyne Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume174,489 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Bioxyne (ASX:BXN) Vs. CHV, DDXS, PREV, TNGN, COM, and MYM

Should you be buying BXN stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Bioxyne, including (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), and 17031 (MYM).

Bioxyne (ASX:BXN) and (CHV) (CNSX:CHV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Bioxyne and (CHV), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bioxyne0000N/A
(CHV)0000N/A

Profitability

This table compares Bioxyne and (CHV)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioxyneN/AN/AN/A
(CHV)N/AN/AN/A

Earnings & Valuation

This table compares Bioxyne and (CHV)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioxyne$2.18 million0.00$-640,145.02A$0.00N/A
(CHV)N/AN/AN/AN/AN/A

(CHV) has lower revenue, but higher earnings than Bioxyne.

Summary

Bioxyne beats (CHV) on 1 of the 1 factors compared between the two stocks.

(DDXS) (OTCMKTS:DDXS) and Bioxyne (ASX:BXN) are both health technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.

Earnings & Valuation

This table compares (DDXS) and Bioxyne's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(DDXS)N/AN/AN/AN/AN/A
Bioxyne$2.18 million0.00$-640,145.02A$0.00N/A

(DDXS) has higher earnings, but lower revenue than Bioxyne.

Analyst Recommendations

This is a summary of current recommendations and price targets for (DDXS) and Bioxyne, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(DDXS)0000N/A
Bioxyne0000N/A

Profitability

This table compares (DDXS) and Bioxyne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(DDXS)N/AN/AN/A
BioxyneN/AN/AN/A

Summary

Bioxyne beats (DDXS) on 1 of the 1 factors compared between the two stocks.

Bioxyne (ASX:BXN) and (PREV) (CNSX:PREV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Bioxyne and (PREV)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioxyne$2.18 million0.00$-640,145.02A$0.00N/A
(PREV)N/AN/AN/AN/AN/A

(PREV) has lower revenue, but higher earnings than Bioxyne.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Bioxyne and (PREV), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bioxyne0000N/A
(PREV)0000N/A

Profitability

This table compares Bioxyne and (PREV)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioxyneN/AN/AN/A
(PREV)N/AN/AN/A

Summary

Bioxyne beats (PREV) on 1 of the 1 factors compared between the two stocks.

(TNGN) (OTCMKTS:TNGN) and Bioxyne (ASX:BXN) are both health technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Earnings and Valuation

This table compares (TNGN) and Bioxyne's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(TNGN)N/AN/AN/AN/AN/A
Bioxyne$2.18 million0.00$-640,145.02A$0.00N/A

(TNGN) has higher earnings, but lower revenue than Bioxyne.

Profitability

This table compares (TNGN) and Bioxyne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(TNGN)N/AN/AN/A
BioxyneN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for (TNGN) and Bioxyne, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(TNGN)0000N/A
Bioxyne0000N/A

Summary

Bioxyne beats (TNGN) on 1 of the 1 factors compared between the two stocks.

138267 (COM.TO) (TSE:COM) and Bioxyne (ASX:BXN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Profitability

This table compares 138267 (COM.TO) and Bioxyne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
138267 (COM.TO)N/AN/AN/A
BioxyneN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for 138267 (COM.TO) and Bioxyne, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
138267 (COM.TO)0000N/A
Bioxyne0000N/A

Valuation & Earnings

This table compares 138267 (COM.TO) and Bioxyne's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
138267 (COM.TO)N/AN/AN/AN/AN/A
Bioxyne$2.18 million0.00$-640,145.02A$0.00N/A

138267 (COM.TO) has higher earnings, but lower revenue than Bioxyne.

Summary

Bioxyne beats 138267 (COM.TO) on 1 of the 1 factors compared between the two stocks.

Bioxyne (ASX:BXN) and 17031 (CNSX:MYM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a breakdown of recent ratings for Bioxyne and 17031, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bioxyne0000N/A
170310000N/A

Profitability

This table compares Bioxyne and 17031's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioxyneN/AN/AN/A
17031N/AN/AN/A

Valuation & Earnings

This table compares Bioxyne and 17031's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioxyne$2.18 million0.00C$-640,145.02A$0.00N/A
17031N/AN/AN/AN/AN/A

17031 has lower revenue, but higher earnings than Bioxyne.

Summary

Bioxyne beats 17031 on 1 of the 1 factors compared between the two stocks.


Bioxyne Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
(DDXS) logo
DDXS
(DDXS)
0.5$0.00flat$0.00N/A0.00
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
TNGN
(TNGN)
0.4N/AN/A$0.00N/A0.00Gap Up
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
Abattis Bioceuticals logo
ATTBF
Abattis Bioceuticals
0.4$0.02flat$0.00N/A0.00Gap Up
Abzena logo
ABZA
Abzena
0.6$15.75flat£0.00N/A0.00
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.73flat$0.00N/A0.00
ACR
Acrux
0.9N/AN/A$0.00$1.61 million0.00High Trading Volume
Gap Up
ACW
Actinogen Medical
0.5N/AN/A$0.00$2.84 million0.00High Trading Volume
Gap Up
1AD
AdAlta
0.5N/AN/A$0.00$4.23 million0.00High Trading Volume
Gap Up
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.81flat$0.00N/A0.00
AHZ
Admedus
0.5N/AN/A$0.00N/A0.00High Trading Volume
Algernon Pharmaceuticals logo
AGNPF
Algernon Pharmaceuticals
0.0$0.13flat$0.00N/A0.00Increase in Short Interest
Gap Up
Almirall logo
LBTSF
Almirall
0.5$15.00flat$0.00N/A0.00
AMBS
Amarantus BioScience
0.5N/AN/A$0.00N/A0.00High Trading Volume
ATX
Amplia Therapeutics
0.8N/AN/A$0.00$894,155.000.00High Trading Volume
Gap Up
ANR
Anatara Lifesciences
0.5N/AN/A$0.00$268,259.000.00High Trading Volume
Gap Up
ANVS
Annovis Bio
0.0N/AN/A$0.00N/A0.00High Trading Volume
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08flat$0.00N/A0.00
ARNI
Arno Therapeutics
0.5$0.01flat$0.00N/A0.00Gap Up
ASCLF
Ascletis Pharma
0.4$0.37flat$0.00N/A0.00News Coverage
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06flat$0.00N/A0.00Increase in Short Interest
AXIM Biotechnologies logo
AXIM
AXIM Biotechnologies
0.4$0.60flat$0.00N/A0.00
BXRXV
Baudax Bio
0.5N/AN/A$0.00N/A0.00High Trading Volume
BerGenBio ASA logo
BRRGF
BerGenBio ASA
0.7$3.52flat$0.00N/A0.00
BGT
Bio-Gene Technology
0.8N/AN/A$0.00$82,795.000.00High Trading Volume
Gap Up
BNO
Bionomics
0.5N/AN/A$0.00$2.19 million0.00High Trading Volume
Gap Up
BIT
Biotron
0.5N/AN/A$0.00$853,026.000.00High Trading Volume
Gap Up
BOT
Botanix Pharmaceuticals
0.5N/AN/A$0.00$6.89 million0.00High Trading Volume
Gap Up
BPH
BPH Energy
0.5N/AN/A$0.00$106,954.000.00High Trading Volume
Gap Up
BTC
BTC Health
0.8N/AN/A$0.00$131,934.000.00High Trading Volume
Gap Up
Cannabics Pharmaceuticals logo
CNBX
Cannabics Pharmaceuticals
0.4$0.22flat$0.00N/A0.00High Trading Volume
Increase in Short Interest
Gap Up
ORHOF
CannaRoyalty
0.7$9.23flat$0.00N/A0.00Gap Down
CDXI
Cardax
0.0N/AN/A$0.00N/A0.00High Trading Volume
CDY
Cellmid
0.5N/AN/A$0.00$6.61 million0.00High Trading Volume
Gap Up
Cerebain Biotech logo
CBBT
Cerebain Biotech
0.0$0.04flat$0.00N/A0.00Increase in Short Interest
Gap Up
CHM
Chimeric Therapeutics
0.3N/AN/A$0.00N/A0.00High Trading Volume
CGYG
China Longyi Group International
0.4$0.00flat$0.00N/A0.00
CLVLY
Clinuvel Pharmaceuticals
1.0$22.74flat$0.00N/A0.00Decrease in Short Interest
CUV
Clinuvel Pharmaceuticals
1.0N/AN/A$0.00$38.34 million0.00High Trading Volume
Gap Up
CELZ
Creative Medical Technology
0.5$0.05flat$0.00N/A0.00News Coverage
CSL logo
CSL
CSL
0.8N/AN/A$0.00$9.98 billion0.00High Trading Volume
Gap Up
Cybin logo
CLXPF
Cybin
1.0$1.46flat$0.00N/A0.00
CYP
Cynata Therapeutics
0.5N/AN/A$0.00$2.59 million0.00High Trading Volume
Gap Up
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
Eastgate Biotech logo
ETBI
Eastgate Biotech
0.5$0.00flat$0.00N/A0.00
EMMBF
Emblem
0.6$1.40flat$0.00N/A0.00
ENZC
Enzolytics
0.0$0.22flat$0.00N/A0.00
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.